-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Ovid Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2015 to 2024.
- Ovid Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $1.26M, a 29.6% decline year-over-year.
- Ovid Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $6.28M, a 13.9% decline year-over-year.
- Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6.28M, a 13.9% decline from 2023.
- Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7.29M, a 11.1% increase from 2022.
- Ovid Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6.56M, a 29.7% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)